Investigate role of miRNA146a and IL-17 level in progressive rheumatoid arthritis disease.

Abstract

Rheumatoid Arthritis (RA) is a chronic, progressive autoimmune disease, involves an intimate relationship between immune cells and cytokines and results in decreased lifespans and higher mortality rates. The goal of the current study was to investigate the impact of MicroRNA (miRNA)146a and interleukin-17 (IL-17) as prognosis markers in RA patients. This case-control study included 120 RA patients who visited the Rheumatology unit at Al-Saddar Medical City in the governorate of Najaf, and 30 normal controls. Venous blood samples were collected from both patients and controls. Blood samples were used for measuring IL-17 levels using an enzyme linked immunosorbent assay (ELISA) testing, and miRNA146a by the reverse transcription polymerase chain reaction (RT-PCR). The results showed higher frequency of RA in women than in men with elevate incidence in patients aged 40-59 years and 1-2 years RA disease duration of. The level of IL-17 was significantly higher in serum of RA patients compared with the control group (p < 0.0001). IL-17 level was significantly increased among the patients in RA stage 4 (p < 0.0001). IL-17 level was significantly increased in patients without treatment compared with treated patients. The expression of miRNA-146a was significantly higher in the patients' group than control group. In conclusion, IL-17 may play critical role in chronic inflammation and can be used as diagnostic biomarker for RA. miRNA-146a is overexpressed in RA patient relative to healthy individuals and it acts as a negative regulator for IL-17.